Shares of CRISPR Therapeutics (NASDAQ: CRSP) dropped almost 15% last month after Wall Street caught wind of results from two studies suggesting that a certain CRISPR tool may be linked to cancer. The gene-editing tool itself doesn't cause the mutation, but instead activates one already present in a cell that can result in genetic instability.
Should you avoid CRISPR Therapeutics stock right now?
Oct 13, 2021 · Shares of the gene-editing titan CRISPR Therapeutics ( CRSP -2.35% ) are seemingly in for a bad day. The biotech's stock dropped by nearly 10% in premarket trading today in response to an early...
Does CRISPR Therapeutics AG (CRSP) beat earnings estimates?
Nov 04, 2021 · Shares of CRISPR Therapeutics ( CRSP -5.54% ) slid 18.4% in October, according to data from S&P Global Market Intelligence. The biotech stock lost ground after the …
Is Maxx chatsko stock a buy for CRISPR Therapeutics?
Dec 05, 2021 · CRISPR Therapeutics stock has continued to fall in early December trading. The company's share price is down roughly 6.9% in the month so far: CRSP data by YCharts .
Is CRISPR Therapeutics a buy for George Budwell?
What happened. Shares of CRISPR Therapeutics ( CRSP 5.38% ) are falling today, down by 9.7% as of 1:53 p.m. EST, after the company announced …
Is Crispr stock a good investment?
Yes, CRISPR Therapeutics boasts explosive upside potential, but it also comes with a decent amount of risk, more so than many investors can handle.Mar 16, 2022
Is Crispr overvalued?
At a high level, most CRISPR stocks are wildly overvalued given their level of maturity. Unlike software companies, it's very difficult for a drug developer to reach a market valuation of $10 billion.Jan 22, 2022
Will Vertex buy Crispr?
Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics. The biotech firm Vertex Pharmaceuticals is paying $900 million to CRISPR Therapeutics for rights to 60% of the profits from sales of a gene-editing therapy called CTX001.Apr 20, 2021
What is the target price for CRSP?
CRISPR Therapeutics AG (NASDAQ:CRSP) The 20 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 146.00, with a high estimate of 220.00 and a low estimate of 64.00. The median estimate represents a +153.65% increase from the last price of 57.56.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) slid 18.4% in October, according to data from S&P Global Market Intelligence. The biotech stock lost ground after the company published weaker-than-expected trial results for one of its key clinical therapies.
So what
While CRISPR Therapeutics framed the results as positive, the tested efficacy levels for CTX110 appear to have fallen short of the market's expectations. The trial found that CTX110 had a 58% overall response rate and a 38% complete response rate in large B-cell lymphoma. Analysts were mixed on the performance and implications.
Now what
CRISPR stock has regained some ground early in November's trading. The company's share price is up roughly 6% in the month so far.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) sank 12.5% in November, according to data from S&P Global Market Intelligence.
So what
CRISPR Therapeutics published its Q3 results on Nov. 3; it delivered a narrower-than-expected loss, but also sales that fell short of the market's expectations. The company posted a loss of $1.67 per share on revenue of roughly $820,000, while the average analyst estimate had called for a per-share loss of $1.75 on revenue of $1.3 million.
Now what
CRISPR Therapeutics stock has continued to fall in early December trading. The company's share price is down roughly 6.9% in the month so far:
What is CRISPR gene editing?
CRISPR Therapeutics is exploring many applications for its gene-editing technology. For instance, CTX001 attempts to engineer cells in bone marrow such that the resulting red blood cells generated can function properly and relieve individuals suffering from sickle cell disease or beta thalassemia.
Where did Maxx graduate from?
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
Where did Maxx graduate from?
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
Is CRISPR still performing?
Despite falling back to earth in 2018, CRISPR stocks have still performed relatively well since launching onto the pubic markets within the last two or so years. CRISPR Therapeutics has gained 161% since its initial public offering (IPO), while Editas Medicine is up 54%. Only Intellia Therapeutics has lost value, delivering a 14% drop to investors since it went public.
